Cardiovascular morbidity in a randomized trial comparing GnRH-agonist and GnRH-antagonist among patients with advanced prostate-cancer and pre-existing cardiovascular disease

David Margel,Avivit Peer,Yaara Ber,Liat Shavit Grievink,Tzlil Tabachnik,Sivan Sela,Guy Witberg,Jack Baniel,Daniel Kedar,Wilhelmina C.M. Duivenvoorden,Eli Rosenbaum,Jehonathan H. Pinthus

Cardiovascular morbidity in a randomized trial comparing GnRH-agonist and GnRH-antagonist among patients with advanced prostate-cancer and pre-existing cardiovascular disease

2019

David Margel
Avivit Peer
Yaara Ber
Liat Shavit Grievink
Tzlil Tabachnik
Sivan Sela
Guy Witberg
Jack Baniel
Daniel Kedar
Wilhelmina C.M. Duivenvoorden
Eli Rosenbaum
Jehonathan H. Pinthus

Abstract:Purpose:Androgen-deprivation therapy (ADT) may increase risk of cardiovascular-disease (CVD). Limited data suggest that gonadotrophin-releasing hormone (GnRH)-antagonist may be associated ...

Keywords:

Randomized controlled trial
Urology
Prostate cancer
Disease
Agonist
GnRH Antagonist
Medicine
Antagonist
Lower risk
Oncology
Internal medicine
Androgen deprivation therapy
Hormone

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations